Exelixis Inc at Barclays Global Healthcare Conference Transcript
Hello, again, everyone. I'm Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to have Exelixis with us. With us today, we have Senior Vice President of Strategy and Investor Relations, Andrew Peters. Thank you so much for joining us.
And I'm sure folks are familiar with the Exelixis story, but maybe it would be helpful to maybe just start with some introductory remarks, and then we'll go into Q&A.
Sure. Thank you again for the invite. Always like being in Miami this time of the year, even though the weather in California is also nice this week. As a reminder, I'm going to be making some forward-looking statements today. So please see disclosures around relative risks in our business in our SEC filings.
So Exelixis is a commercial oncology company really built around our lead molecule, CABOMETYX, cabozantinib, which is a tyrosine kinase inhibitor that targets VEGF as well as a whole
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
